| Chemotherapy "Bath" May Stop Mesothelioma Spread |
There is more evidence that washing heated chemotherapy drugs through the open body cavity after mesothelioma surgery may help stop the cancer from spreading.
A team at the Washington Cancer Institute followed the movement and absorption of these drugs – known as pharmacokinetics – to assess their potential for effectively killing spreading mesothelioma cells without harming healthy tissues. Specifically, they were studying people who had one of the rarest forms of mesothelioma, called peritoneal mesothelioma. In these patients, mesothelioma in the membrane around their abdominal organs can progress up into the pleural space around the lungs.
During a surgery called pleurectomy and decortication (P/D), the surgeon may remove all or part of the diseased pleural membrane and scrape cancer cells off the surface of the lungs or the walls of the body cavity. To help kill mesothelioma cells left behind after P/D, surgeons may use hyperthermic intrathoracic chemotherapy. As with any chemotherapy, the challenge is to destroy mesothelioma cells with as little damage as possible to healthy cells.
To assess hyperthermic intrathoracic chemotherapy's ability to do that, the Washington Cancer Institute team washed a solution of the chemotherapy drugs mitomycin C and doxorubicin into the body cavity after a P/D operation. They then monitored the concentration of these agents in the tissues as well as in the blood plasma.
In a summary of their findings, lead study author Paul Sugarbaker writes, "Our results showed a persistent high concentration of intrapleural (around the lungs) drug as compared to plasma concentrations." When they compared the clearance of the drugs from the body cavity, they found that more chemotherapy medicines stayed in the thoracic (upper body) cavity than stayed in the abdomen and pelvis, suggesting a longer-lasting effect on the pleural mesothelioma cells without too much concentration of the toxic chemicals in the blood.
The authors suggest that these findings provide "a strong pharmacologic rationale" for hyperthermic intrathoracic chemotherapy in people with metastatic peritoneal mesothelioma. The research appears in the most recent issue of Gastroenterology Research and Practice.
Sources:
Sugarbaker, P, "Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectom y and Decortication", April 5, 2012, Epub ahead of print.
© Surviving Mesothelioma and Cancer Monthly. All rights reserved.
DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.
